What is Abliva AB (publ) (ABLI.ST)?

Abliva AB (publ) (ABLI.ST) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

Abliva AB (publ) (ABLI.ST)

Stock analysis · STO · Healthcare · Biotechnology

Market Cap

N/A

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

0.75

Day Range

N/A

52-wk Range

N/A

Avg Volume

N/A

Volume

N/A

Abliva AB (publ) (ABLI.ST) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Feb 20, 2018

EPS $-0.23 vs est. $-1.30

Beat by $1.07

Proprietary Signals

Signal snapshot temporarily unavailable.

About Abliva AB (publ)

Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).